LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT): M&A transaction — LIXTE acquires Liora Technologies' proton therapy platform; consideration includes stock, crypto, cash, royalty

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

Consideration: 2,700 Series C Preferred shares (convertible to 2.7M common), 10.56 BTC + 300 ETH, $440K cash, and 10% royalty on net revenue up to $45M.
Liora's LiGHT proton therapy system installed at Daresbury Laboratory in UK; $300M+ invested to date.
Acquisition closed Nov 24, 2025; Liora becomes wholly owned subsidiary of LIXTE.
Series C Preferred is non-voting, convertible subject to 19.99% limit until shareholder approval at 2026 annual meeting.
CEO says LiGHT platform complements LB-100 pipeline and enables potential recurring revenue model.

item 1.01 item 2.01 item 3.02 item 5.03 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

LIXTE BIOTECHNOLOGY HOLDINGS, INC.: Filed Certificate of Designations creating Series C Convertible Preferred Stock with 2,700 shares, $1,000 stated value, no dividends, limited voting rights, liquidation preference senior to junior securities, convertible into common stock subject to beneficial ownership limitations (effective 2025-11-24).

Change: charter amendment
Effective: 2025-11-24

Exact text from the filing

On November 24, 2025, the Company filed a Certificate of Designations of Preferences, Rights and Limitations of Series C Convertible Preferred Stock (the “ Certificate of Designation ”) with the Secretary of State of the State of Delaware.

View on SEC.gov

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

LIXTE BIOTECHNOLOGY HOLDINGS, INC. completed an acquisition involving Orbit Capital Inc. for 2,700 shares of the Company's Series C Preferred Stock, $1,000 stated value per share; 10.56 Bitcoin and 300 Ethereum; $440,000 in cash; and a royalty agreement (closed 2025-11-24).

Action: acquisition
Counterparty: Orbit Capital Inc.
Consideration: 2,700 shares of the Company's Series C Preferred Stock, $1,000 stated value per share; 10.56 Bitcoin and 300 Ethereum; $440,000 in cash; and a royalty agreement
Closing: 2025-11-24

Exact text from the filing

pursuant to a lease agreement. At the closing, the Company agreed to pay the following consideration (the “ Consideration ”) in exchange for the Shares: (i) issue to Seller 2,700 shares of the Company’s Series C Preferred Stock, $1,000 stated value per share (the “ Series C Preferred Stock ”) having such rights and preferences as set forth in the

View on SEC.gov

89 governance changes filed in the last 30 days. Browse all governance changes →

LIXTE BIOTECHNOLOGY HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001493152-25-024996

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.